Navigation Links
Cancer categories recast in largest-ever genomic study
Date:8/7/2014

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.

In the largest study of its kind to date, scientists analyzed molecular and genetic characteristics of more than 3,500 tumor samples of 12 different cancer types using multiple genomic technology platforms.

Cancers traditionally have been categorized by their "tissue of origin"such as breast, bladder, or kidney cancer. But tissues are composed of different types of cells, and the new work indicates that in many cases the type of cell affected by cancer may be a more useful guide to treatment than the tissue in which a tumor originates.

The study, published August 7, 2014 in the online edition of Cell, was conducted as part of The Cancer Genome Atlas (TCGA) initiative spearheaded by the National Cancer Institute and National Human Genome Research Institute, both part of the National Institutes of Health.

In the new work, TCGA Research Network scientists analyzed DNA, RNA, and protein from 12 tumor types using six different genomic technologies to see how different tumor types compare to one another. The team arrived at a classification based on 12 cancer subtypes. Five of these matched up well with tissue-of-origin classifications, but several newly identified subtypes were seen to affect a variety of tissues.

"This genomic study not only challenges our existing system of classifying cancers based on tissue type, but also provides a massive new data resource for further exploration, as well as a comprehensive list of the molecular features distinguishing each of the newly described cancer classes," said co-senior author Christopher Benz, MD, professor at the Buck Institute for
'/>"/>

Contact: Peter Farley
peter.farley@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Scientists uncover key piece to cancer cell survival puzzle
2. Largest cancer genetic analysis reveals new way of classifying cancer
3. Gut Bacteria May Reveal Colon Cancer, Study Finds
4. New Cancer Classification System Might Boost Patient Outcomes
5. Cell mechanics may hold key to how cancer spreads and recurs
6. Sharp Rise in Risk With New Breast Cancer Gene, Scientists Say
7. NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer
8. Gut microbiome analysis improved noninvasive colorectal cancer screening
9. Young Cancer Patients at Loma Linda University Children's Hospital Treated to an Afternoon of Fun with UCLA Football Players, Sponsored by Stater Bros
10. Gene increases risk of breast cancer to 1 in 3 by age 70
11. Daily Aspirin May Help Prevent Cancer, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... TX (PRWEB) , ... July 01, 2015 , ... As ... another symptom found in a significant number of women: leg pain. Northeast Houston Vein ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Trevor L. Williams, ... South Florida and continued at USF earning a Master’s degree in Microbiology. He graduated ... member of the American Dental Association, the Florida Dental Association and the Academy of ...
(Date:7/1/2015)... ... 01, 2015 , ... Element Blue ™, a leading ... it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is ... multiple sources providing an environment where users can view and compare real-time and ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting ... a top ten list they hope will guide future mesothelioma research. Surviving Mesothelioma ... it now. , More than 450 mesothelioma patients, caregivers, and healthcare ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... ... ... , , ... HARRISBURG, Pa. , ...
... ... ... ... ...
... alliance the Multilateral Initiative on Malaria (MIM), which advocates ... research environments in Africa. Malaria research has historically been ... has led to a huge gap in knowledge in ... in those areas where people are most affected by ...
... ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ... San Diego, CA (PRWEB) February ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... ... ... ...
Cached Medicine News:Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 2Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 2Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 4Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 5Health News:Malaria research must be based in Africa 2Health News:Flexible Assembly Systems Announces New Torque Calculator App for the iPhone 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9
(Date:7/1/2015)... The global mHealth market ... 49,119.2 million by 2020, according to a new study ... to remain the dominant and fastest growing market segment, ... and an estimated CAGR of 49.7% from 2014 to ... Browse full research report with TOC on ...
(Date:7/1/2015)... , July 1, 2015 ... its Executive Board. Mr. Gert Weber has ... Invest AG as Chief Executive Officer (CEO) ... July 1 st , 2015. Mr. Weber brings more ... technological industries and has filled various executive management positions, ...
(Date:6/30/2015)... 2015 Ansell, a global leader ... of the first Ansell Cares ® H.E.R.O. ... The 2015 award, organised in partnership with the European ... display exceptional skill and quality in patient care, and ... Award ceremonies are taking place today in the winners, ...
Breaking Medicine Technology:mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2Ansell Announces European O.R. Nurse Hero Award Winners 2Ansell Announces European O.R. Nurse Hero Award Winners 3
... TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced ... luliconazole, one of the most potent and broad spectrum ... foot). The study was designed to assess the ... 14 days compared with once daily for 28 days. ...
... and KENILWORTH, N.J., Oct. 6 Centocor Ortho Biotech ... today that the European Commission has approved SIMPONI(TM) (golimumab) ... moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic ... , In the European Union, SIMPONI is approved ...
Cached Medicine Technology:TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal 2TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
M2 cemented hip stem....
Cemented foundation 450 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The link ribbed hip stem for cementless primary hip replacement surgery....
Medicine Products: